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ORIGINAL ARTICLEPrevalence of multidrug-resistant tuberculosis cases among HIV-positive
and HIV-negative patients eligible for retreatment regimen in Togo using
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Research Council Unit, Banjul, Gambia, 3) Service de Pneumophysiologie, CHU Sylvanus Olympio, Lomé, Togo and 4) Emory Vaccine Center, Emory University
School of Medicine, Atlanta, GA, USAAbstractDrug-resistant tuberculosis (TB) is emerging as an important health problem in Togo. From sputum of previously treated TB patients,
multidrug-resistant (MDR) TB was diagnosed in 24% (10/42) patients via GeneXpert MTB/RIF compared to 25% (6/24) patients via
conventional drug susceptibility testing (BACTEC MGIT 960 system). The agreement between these two methods to detect MDR-TB is
excellent. However, GeneXpert MTB/RIF offers the advantage of rapidly detecting Mycobacterium tuberculosis complex in sputum samples
in instances where the cultures are negative (33%, 14/42) or contaminated (9.5%, 4/42). GeneXpert MTB/RIF permitted us to estimate
the prevalence of MDR-TB in previously treated TB patients and to improve TB diagnostics among HIV-positive and -negative patients in
Togo, where culturing M. tuberculosis complex from sputum samples is challenging.
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E-mail: tadekam@emory.eduIntroductionMycobacterium tuberculosis is one of the world’s most devas-
tating human pathogens. Each year more than nine million
people develop active TB; two million die from this disease, and
a third are associated with HIV coinfection [1]. The current
vaccine for tuberculosis (TB), bacillus Calmette-Guérin, has
variable (mostly poor) efﬁcacy in protecting against pulmonary
TB in children and adults [2,3]. TB control is further threatened
by the emergence of multidrug-resistant (MDR), extremely
drug-resistant and totally drug-resistant strains ofM. tuberculosis
[4]. In new TB cases the proportion of MDR-TB (isolates that
exhibit resistance to at least rifampicin (RIF) and isoniazidw Microbe and New Infect 2015; 8: 24–27
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p://dx.doi.org/10.1016/j.nmni.2015.09.001(INH)) ranged from 0 to 22.3%. The highest proportion of
MDR-TB reported was 60% among previously treated cases
[4,5].
Using accurate and early detection tests to manage drug-
resistant TB cases is of great urgency for countries facing high
proportions of drug resistance and countries with a population
heavily coinfected with HIV [5,6]. The prevalence of MDR-TB
has been estimated to be low in sub-Saharan Africa, where
surveillance of drug resistance is notably limited [1]. In Togo
little work has been done to determine the exact prevalence of
MDR-TB. The recently introduced GeneXpert MTB/RIF assay
detects the presence of M. tuberculosis complex DNA and its
susceptibility to RIF in a single reaction. Ninety-ﬁve per cent of
RIF-resistant isolates also exhibit resistance to INH [7–9].
Therefore, the detection of RIF resistance may serve as a sur-
rogate marker for MDR M. tuberculosis [8–10].
The objective of this study was to determine the prevalence
of MDR among previously treated HIV-positive and -negative
patients and to evaluate the performance of GeneXpert MTB/
RIF in detecting MDR cases in Togo.European Society of Clinical Microbiology and Infectious Diseases
nses/by-nc-nd/4.0/)
NMNI Dagnra et al. MDR-TB in Togo 25Materials and methodsTABLE 1. Distribution of type of retreatment cases and
resistance proﬁle
Resistance n (%) GeneXpert MTB/RIF, n (%)
Relapse 22 (52.38) 6 (27.27)
Failure 14 (33.34) 2 (14.28)
Default 6 (14.28) 2 (33.34)
Total 42 (100) 10 (25)Sample and selection criteria
This study was conducted in Togo in the mycobacteria refer-
ence laboratory from January 2013 to June 2013. Ethical
approval was obtained from the Université de Lomé institu-
tional review board. All participants provided written informed
consent for the collection of samples and subsequent analyses.
Sputum samples were collected from previously TB-treated
HIV-positive and -negative patients who had TB according to
the deﬁnition established by the World Health Organization
(WHO): relapse, failure or default (https://www.cap-tb.org/
resources/tb-case-deﬁnitions-revision-6-may-2011). Samples
were obtained from patients all over the country and were sent
to the reference laboratory in a cooler box (4–8°C) within 24
hours of sample collection for the closest sites and stored in a
refrigerator for microscopy, culture, Mycobacteria Growth
Indicator Tube (MGIT) drug susceptibility testing (DST) and
GeneXpert MTB/RIF assay.
HIV testing
Alere Determine HIV-1/2 (Alere, Yavne, Israel) and HIV Tri-dot
(J. Mitra, New Delhi, India) tests were used to screen for HIV-1
and HIV-2 infection.
Microscopy
Microscopy was performed on all collected samples using Ziehl-
Neelsen staining, which is available in all peripheral health care
centre laboratories in Togo.
Culture
Both the BACTEC MGIT 960 system (Becton Dickinson,
Sparks, MD, USA) (liquid media) and Löwenstein-Jensen agar
were systematically used for sputum culture samples, irre-
spective of smear microscopy result. Positive growth
without contaminant was conﬁrmed by Ziehl-Neelsen
staining and by the rapid test conﬁrmation kit (i.e. MPT64
protein detection-based immunochomatographic test; SD
Bioline Kit, Standard Diagnostics, Yongin-si, Korea) [11]. The
interpretation of results was based on the manufacturer’s
instructions. Positive results were considered as belonging
to M. tuberculosis complex. Negative results were regarded
as atypical mycobacteria and were not taken into account in
this study.
Drug susceptibility testing
Conventional DST using the BACTEC MGIT 960 system [12]
and GeneXpert MTB/RIF (Cepheid, Sunnyvale, CA, USA)
[13,14] were used simultaneously to screen all cases for anyNew Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on beha
This is an open access artiresistance pattern present. The interpretations of results were
based on the manufacturer’s instructions.
Statistical analysis
Agreement, sensitivity and speciﬁcity, and values of the BAC-
TEC MGIT 960 system for DST compared to GeneXpert MTB/
RIF were calculated for RIF. The agreement between the two
methods was determined by the κ statistic. The κ value, a
measure of test reliability, was interpreted as follows: <0.2,
poor; 0.21 to 0.4, fair; 0.41 to 0.6, moderate; 0.61 to 0.8, good;
and 0.81, excellent [15].ResultsA total of 42 sputum samples were collected from previously
TB-treated patients in 15 peripheral health care centres: CMS
Adakpame (n = 3), CMS Nukafu (n = 1), CMS Kodjoviakope
(n = 1), CMS Amoutive (n = 1), CMS Be (n = 1), CMS Guerin-
kouka (n = 2), CHU Sokode (n = 17), Hopital District 2 (n = 1),
Hopital Be (n = 1), CLT Zio (n = 2), CDT Bassar (n = 1),
Polyclinic Tsevie (n = 2), Polyclinic Aneho (n = 1), Polyclinic
Kara (n = 3) and Hopital Tabligbo (n = 3). There were 27 (64%)
male and 15 (36%) female subjects for a male/female sex ratio of
1.8:1. One patient was younger than 15 years old, 32 were aged
between 15 and 45, eight were aged 45 to 65 and one was older
than 65. The average age was 34.5 years; most patients fell
between the ages of 15 and 45.
According to the WHO TB case deﬁnition, of the 42 cases,
22 were relapse cases (52.38%), 14 were failure cases (33.34%)
and six were default cases (Table 1). Only 31 (73.8%) of 42 had
consented to undergo HIV testing. Seven (22.6%) of these 31
patients were positive for HIV-1; no cases of HIV-2 were
detected. Three of these seven were relapse cases and four
were failure cases. Fourteen of the 42 total cases were culture
negative, and four samples were contaminated.
Using the BACTEC MGIT 960 system for DST, 13 (54%) of
24 were susceptible to all the drugs, six (25%) were resistant to
at least RIF and INH combined but not to other drugs and ﬁve
(21%) were monoresistant, as follows: streptomycin (n = 2),
ethambutol (n = 1) and pyrazinamide (n = 2) (Fig. 1). Among thelf of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 8, 24–27
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
FIG. 1. Distribution of drug susceptibility testing proﬁle based on
BACTEC MGIT 960 system.
26 New Microbes and New Infections, Volume 8 Number C, November 2015 NMNI42 sputum samples, the sensitivity and speciﬁcity of the BAC-
TEC MGIT 960 system for detecting MDR-TB were 60% and
100%, respectively.
GeneXpert MTB/RIF detected M. tuberculosis complex from
the 42 sputum samples even though culture results were
negative (n = 14) or contaminated (n = 4). Among the 42
samples ten (24%) exhibited resistance to RIF. Two of ten in-
stances of RIF resistance were detected by GeneXpert MTB/
RIF and were positive for HIV (Table 2), one with relapse and
the other with failure. Overall, the six MDR-TB cases detected
by the BACTEC MGIT 960 system were conﬁrmed by Gen-
eXpert MTB/RIF. There was excellent agreement between the
BACTEC MGIT 960 system and GeneXpert MTB/RIF for DST
(κ = 1).DiscussionAlthough TB remains one of the most difﬁcult infections to
treat, the current Direct Observed Treatment Short regimen,
which usually takes 6 to 9 months of continuous chemotherapy,
is quite effective in treatment of drug-susceptible TB. Mutations
in drug target genes have contributed to the evolution of
M. tuberculosis strains that are resistant to the currently avail-
able ﬁrst-line TB antibiotics [9].
In this study, ﬁrst-time diagnosed TB patients received
chemotherapy (RIF, INH, ethambutol and pyrazinamide). Pa-
tients who improved after 2 months of intensive-phase therapy
then continued with only RIF and INH therapy for 4 months.
Treatment was considered a failure if the patient’s sputumTABLE 2. Detection of rifampicin resistance by GeneXpert
MTB/RIF
GeneXpert MTB/RIF HIV result n
Total 42
Rifampicin resistance Negative 8
Positive 2
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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licesmear or culture remained positive at 5 months or later during
treatment; the case was considered a relapse when a previously
treated patient developed another episode of TB after a
completed treatment and had a negative smear and/or culture
result [5,6,11,16,17]. Forty-two previously treated patients
were enrolled onto this study; subjects had an HIV prevalence
of 22.58% (only 31 consented to an HIV test). Most affected
patients were within the active population range of 15 to 45
years.
The HIV epidemic caused a dramatic increase in TB inci-
dence in sub-Saharan countries. In South Africa the HIV-driven
rise in TB incidence was accompanied by escalating rates of TB
drug resistance [18]. In Togo a previous study found that the
prevalence of TB-HIV coinfection was 23.7% in TB patients
[19]. In our study more than half of the participants were
relapse cases (52.4%), followed by failure cases (14%). The
overall prevalence of MDR-TB based on the BACTEC MGIT
960 system for DST was 25% (6/24) and was conﬁrmed by
GeneXpert MTB/RIF (24%, 10/42) among retreatment cases.
According to a 2008 WHO report [20] Estonia reported
52.1% MDR-TB among previously treated cases, Azerbaijan
(Baku City) reported 55.8%, Uzbekistan (Tashkent) reported
60.0% and Lebanon reported 62.5%. The Russian Federation
reported data on retreatment cases in Orel Oblast only.
Sixteen settings reported MDR-TB of 25% or higher among
previously treated cases [5]. These data correlate with our
ﬁndings in Togo, with the majority found among relapse cases,
followed by failure cases. Repeated misuse or intense use of
these few drugs has led to the sequential accumulation of
mutations, resulting in the emergence of strains simulta-
neously resistant to multiple existing TB drugs [9,10,21]. Un-
like the situation in other bacteria, where acquired drug
resistance is generally mediated through horizontal transfer by
mobile genetic elements such as plasmids, transposons or
integrons, in M. tuberculosis acquired drug resistance is caused
mainly by spontaneous mutations in chromosomal genes,
producing the selection of resistant strains during suboptimal
drug therapy [10]. In our study, only 24 were detected as
culture positive due to the antibiotic pressure on the physi-
ology of the bacteria (when the patient was receiving treat-
ment), or in the paucibacillary sample for relapse cases. DST
was performed only on these 24 isolates, and 25% (n = 6)
were MDR. Compared with the BACTEC MGIT 960 system
for DST, GeneXpert correctly identiﬁed 98.2% (95% conﬁ-
dence interval, 91.5–99.9) of RIF-resistant and 95.5% (95%
conﬁdence interval, 85.8–99.2%) of RIF-susceptible specimens
[22]. In our study all 42 cases detected as M. tuberculosis
complex had 100% sensitivity.
The MTB/RIF test is a simple method, and routine staff with
minimal training can use the system. The test appeared to be asEuropean Society of Clinical Microbiology and Infectious Diseases, NMNI, 8, 24–27
nses/by-nc-nd/4.0/)
NMNI Dagnra et al. MDR-TB in Togo 27sensitive as culture with smear-positive specimens but less
sensitive with smear-negative pulmonary and extrapulmonary
specimens that included low numbers of bacilli [14]. The rpoB
gene represents a much better molecular target for the
simultaneous detection of TB and the key form of drug resis-
tance [23]. The GeneXpert assay was highly effective for TB
diagnosis and identiﬁcation of RIF-resistant strains in smear-
negative samples [8,13]. All ten MDR cases detected as RIF
resistant with GeneXpert were conﬁrmed by MGIT DST
testing with an association to at least INH resistance. This
demonstrates the accuracy of GeneXpert to detect MDR cases.
The detection of RIF resistance may therefore serve as a sur-
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